Incyte (INCY) is down about 3% today after reporting first-quarter 2026 results that topped Wall Street expectations, but issuing full-year revenue guidance that trailed consensus forecasts. Investors focused on the outlook gap rather than the EPS beat, pushing the stock lower in early trading. �citeturn1search2turn1search3

The company reported total revenue of $1.27 billion in Q1 2026, up 21% year over year, with total net sales of $1.10 billion (+20%). Product performance included Jakafi net sales of $758 million (+7%) and Opzelura cream net sales of $143 million, but the market reaction centered on the company’s full-year revenue guide being meaningfully below analyst expectations cited in market coverage. �citeturn3view0turn1search2

Alongside results, Incyte highlighted multiple upcoming regulatory milestones and late-stage readouts, including continued advancement of povorcitinib (including positive Phase 3 vitiligo outcomes and prior FDA acceptance of an HS NDA) and ongoing Phase 3 activity across the portfolio. Separately, the company announced a CFO appointment, with Suketu (Suky) Upadhyay set to assume the role effective May 4, 2026, adding another headline for investors to digest on an earnings day. �citeturn3view0turn2view0turn3view2

The next catalyst is management’s commentary on the earnings call and any color on demand, payer dynamics, and timing assumptions embedded in the 2026 outlook. Investors will also be tracking the cadence of late-stage data disclosures through the second half of 2026 and the path to the company’s anticipated approvals and launches from mid-2026 into early 2027. �citeturn3view0turn1search6